NAMS | NewAmsterdam Pharma Company N.V. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	15.84 - 16.36
52 Week Range	5.63 - 26.35
Beta	0.19
Implied Volatility	90.66%
IV Rank	36.30%
Day's Volume	173,461
Average Volume	345,691
Shares Outstanding	90,015,400
Market Cap	1,425,843,936
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-02-09

Valuation
Profitability
Growth
Health
P/E Ratio	-6.05
Forward P/E Ratio	N/A
EPS	-2.62
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	57
Country	Netherlands
Website	NAMS

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

NAMS's peers: ASLN, CLGN, CMPX, GANX, GNLX, IMRX, IOBT, IVA, MIST, NVCT, REPL, RLMD, PMN, NAMSW, GLUE, CGEM, CRNX, PRTC, MRUS, MLYS, ELYM, ANEB, JANX, RZLT, MOLN, PEPG, CYT

*Chart delayed

Analyzing fundamentals for NAMS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see NAMS Fundamentals page.

Watching at NAMS technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on NAMS Technicals page.